Hemogenyx Pharmaceuticals PLC
LSE:HEMO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
AllianceBernstein Holding LP
NYSE:AB
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (0), the stock would be worth GBX-0.84 (100% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -11.1 | GBX786.5 |
0%
|
| Industry Average | 0 | GBX-0.84 |
-100%
|
| Country Average | 0 | GBX-1.39 |
-100%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
Hemogenyx Pharmaceuticals PLC
LSE:HEMO
|
50.6m GBP | -11.1 | -6.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -194 446.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
355.3B USD | 14.1 | 84.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.9B USD | 14.1 | 24.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
165.8B USD | 12.2 | 19.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.5B USD | 21 | 28 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -581 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81B USD | 13.4 | 18 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.4B EUR | 41.5 | 38.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -66.6 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.2B AUD | 10.5 | 30.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0 |
| Max | 743.2 |
Other Multiples
Hemogenyx Pharmaceuticals PLC
Glance View
HemoGenyx Pharmaceuticals Plc operates as a biopharmaceutical company, which engages in the development of novel therapies to transform bone marrow and blood stem cell transplantation. The firm is engaged in the discovery, development, and commercialization of a suite of products to address the problems associated with the treatment of blood disorders, such as cancers and autoimmune diseases, with viral infections, and with bone marrow, or hematopoietic stem cell, transplants. The Company’s product candidates include CDX antibody, CAR-T cell therapy, Hu-PHEC stem cell therapy, Humanised mice, and CBR platform. Its CDX antibody product, is a bispecific antibody targeting a form of relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia (ALL), and myelodysplastic syndrome. CAR-T cell therapy is a chimeric antigen receptor T-cells that are engineered for use in immunotherapy. The Company’s human postnatal hemogenic endothelial cells (Hu-PHECs) are a type of cell therapy that generate cancer-free hematopoietic stem cells for use in transplants to treat blood disorders.
